EE459 Is Adding Ribociclib to Fulvestrant Cost-Effective in Treating Post-Menopausal Women with HR+/ HER2- Advanced Breast Cancer - a US Payer Perspective Cost-Utility Analysis.

Subjects

Subjects :

*METASTATIC breast cancer
*COST effectiveness
*POSTMENOPAUSE
*FULVESTRANT

Details

Language :

English

ISSN :

10983015

Volume :

25

Issue :

7

Database :

Academic Search Index

Journal :

Value in Health

Publication Type :

Academic Journal

Accession number :

157695711

Full Text :

https://doi.org/10.1016/j.jval.2022.04.707